# Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations

> **NCT01246401** · PHASE1,PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 151 (actual)

## Conditions studied

- HIV
- AIDS
- Opioid Dependence
- Drug Dependence

## Interventions

- **DRUG:** Extended-Release Naltrexone

## Key facts

- **NCT ID:** NCT01246401
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2016-03
- **Final completion:** 2016-07
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2020-03-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01246401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01246401, "Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01246401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*